The groups behind the petition include the American College of Obstetricians and Gynecologists, SisterReach, Physicians for Reproductive Health and the Expanding Medication Abortion Access Project. To clear access to the FDA-approved medication, the petition asks the FDA to submit a Supplemental New Drug Application or “eliminate or modify mifepristone’s Risk Evaluation and Mitigation Strategy so that it is not unduly burdensome for that use.”
After the Supreme Court overturned Roe v. Wade in June, access to mifepristone waned as pharmacies and health systems scrambled to understand new laws. As a result of the landmark decision, in some states, CVS policy requires workers to confirm a patient’s mifepristone prescription is not intended for abortion.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
